Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AnnexonANNX +2.76%34 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates ANNX with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Annexon ranks worse than 105932.1% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Annexon's Net Income for the
three
months ended in Mar. 2026 was $-44.14 Mil. Annexon's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Annexon's net margin for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Annexon's Net Margin % or its related term are showing as below:
ANNX's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.635 * Ranked among companies with meaningful Net Margin % only.
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Annexon Net Margin % Related Terms
Annexon Net Margin % Historical Data
* Premium members only.
The historical data trend for Annexon's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Annexon's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annexon Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annexon's Net Margin % distribution charts can be found below:
* The bar in red indicates where Annexon's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annexon (ANNX) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Annexon and its competitors. According to the industry distribution chart, Annexon ranks #999999 out of 944 companies in the Biotechnology industry.
Is Annexon's Net Margin % too high?
Annexon's current Net Margin % is 0.00%. Based on the distribution chart, Annexon ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annexon has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Annexon's Net Margin % compare to ABUS and TBPH?
According to the Biotechnology industry distribution chart, Annexon ranks #999999 out of 944 companies for Net Margin %. This places Annexon in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Annexon and its competitors. Annexon's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexon stock overvalued right now?
Annexon (ANNX) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Annexon's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Annexon (ANNX), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
34GF Score
Get the complete analysis for ANNX
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANNX has been successfully added to your 
